Bulk Pharmaceutical API Sources for dichlorphenamide

Bulk Pharmaceutical API Sources for dichlorphenamide

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-004-285-635
Amadis Chemical		A21072
TimTec		SBB058142
TimTec		ST51014977
AKos Consulting & Solutions		AKOS015899860
Finetech Industry Limited		FT-0648264

Dichlorphenamide API Sourcing Landscape

Last updated: February 19, 2026

This analysis examines the current global supply of dichlorphenamide Active Pharmaceutical Ingredient (API), identifying key manufacturers, regulatory standing, and potential supply chain risks. Dichlorphenamide, indicated for the treatment of primary hyperkalemic and acetazolamide-responsive periodic paralysis, faces a concentrated manufacturing base with implications for pricing and availability.

What is the global production capacity for dichlorphenamide API?

The global production capacity for dichlorphenamide API is limited, with a small number of manufacturers holding the primary supply. Precise figures for total annual capacity are not publicly disclosed by these entities, but market analysis suggests a supply that adequately meets current demand, though significant increases in demand could strain existing capabilities.

Key Manufacturers of Dichlorphenamide API:

• CordenPharma International GmbH: A significant European manufacturer with a history of producing complex APIs.
• Sun Pharma Advanced Research Company Ltd.: An Indian pharmaceutical research and manufacturing company with a notable presence in API production.
• Astron Chemicals Pvt. Ltd.: Another Indian-based company identified as a producer of dichlorphenamide API.

These manufacturers operate specialized facilities capable of handling the multi-step synthesis required for dichlorphenamide. Their production is largely driven by contracted manufacturing agreements with finished dosage form (FDF) producers.

Which regulatory bodies oversee dichlorphenamide API manufacturing?

Dichlorphenamide API manufacturing is overseen by major pharmaceutical regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO). Compliance with Good Manufacturing Practices (GMP) is mandatory for all API producers supplying regulated markets.

Regulatory Filings and Inspections:

• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies like the FDA to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. These filings are critical for FDF manufacturers seeking to use the API in their approved drug products.
• GMP Inspections: Facilities are subject to periodic inspections by regulatory authorities to ensure ongoing compliance with GMP standards. Successful inspections are prerequisite for continued supply to the US and EU markets. For example, CordenPharma's facilities have undergone such inspections, as have those of Indian API manufacturers seeking to supply regulated markets.
• Certificate of Suitability (CEP): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) can be an important indicator of API quality and compliance.

The regulatory landscape for dichlorphenamide API is stringent, requiring substantial investment in quality control and assurance systems.

What are the primary synthesis routes and their implications for API cost?

The synthesis of dichlorphenamide involves several chemical steps, typically starting from readily available chemical precursors. While specific proprietary routes vary, common pathways involve halogenation and amidation reactions. The complexity of these routes, coupled with the specialized equipment and stringent quality controls required, contributes to the overall cost of the API.

General Synthesis Considerations:

1. Starting Materials: Precursors such as dichloromaleic anhydride or related chlorinated cyclic compounds are often employed. Sourcing and the cost of these raw materials can fluctuate.
2. Reaction Conditions: The process requires controlled reaction conditions, including specific temperatures, pressures, and catalysts, which necessitate investment in advanced chemical processing equipment.
3. Purification: Multi-stage purification processes, including crystallization and chromatography, are essential to achieve the high purity levels required for pharmaceutical use (typically >98.5%). These steps are often yield-limiting and contribute significantly to manufacturing costs.
4. Waste Management: The synthesis may generate hazardous byproducts requiring specialized disposal, adding to operational expenses.

The cost of dichlorphenamide API is influenced by:

• Scale of Production: Larger batch sizes can lead to economies of scale, reducing per-kilogram costs. However, the niche nature of dichlorphenamide limits the potential for massive scale-up compared to blockbuster drugs.
• Yield Optimization: Continuous process improvement to maximize reaction yields and minimize waste directly impacts cost efficiency.
• Raw Material Volatility: Fluctuations in the global market price of key chemical precursors can affect API cost.
• Regulatory Compliance Costs: Maintaining GMP compliance, including validation, testing, and documentation, represents a substantial ongoing cost.

What is the geopolitical and supply chain risk associated with dichlorphenamide API sourcing?

The concentrated nature of dichlorphenamide API manufacturing, particularly with a significant portion of production originating from India, presents specific geopolitical and supply chain risks.

Key Risk Factors:

• Geographic Concentration: Reliance on a limited number of manufacturers, predominantly in India, creates vulnerability to disruptions.
• Geopolitical Instability: Political events, trade disputes, or regional conflicts in the primary sourcing countries could impact supply chains.
• Logistical Challenges: International shipping delays, customs issues, or increased freight costs can affect timely delivery.
• Pandemic-Related Disruptions: As demonstrated by recent global events, widespread health crises can lead to factory shutdowns, labor shortages, and transportation restrictions.
• Regulatory Changes: Evolving environmental regulations or changes in trade policies in manufacturing countries could affect production costs and availability.
• Quality Control Issues: A single quality failure or recall at a major manufacturing site could have a cascading effect on the global supply.

Mitigation Strategies for FDF Manufacturers:

• Dual Sourcing: Identifying and qualifying at least two API manufacturers is a primary strategy to mitigate single-source dependency.
• Geographic Diversification: Seeking manufacturers in different geopolitical regions can reduce overall risk.
• Inventory Management: Maintaining adequate safety stock of API can buffer against short-term supply disruptions.
• Contractual Safeguards: Negotiating robust supply agreements with clear delivery terms, quality assurance clauses, and force majeure provisions.
• Supplier Audits: Conducting regular and thorough audits of API manufacturers to ensure ongoing compliance with quality and ethical standards.

The current landscape indicates that while demand for dichlorphenamide is relatively stable, supply chain resilience requires active management due to its concentrated manufacturing base.

How does the patent landscape impact dichlorphenamide API sourcing?

The primary patents covering dichlorphenamide itself have long expired. Dichlorphenamide was first approved by the FDA in 1960. This means that the molecule is in the public domain, and its generic synthesis is permissible. The patent landscape therefore does not restrict the manufacturing or sale of the API itself.

Implications of Patent Expiration:

• Generic Competition: The absence of patent protection on the molecule allows multiple manufacturers, particularly in India and China, to produce generic dichlorphenamide API.
• Price Pressure: Generic competition typically leads to lower API prices due to increased supply and a more fragmented market.
• Focus on Process Patents: While the molecule is off-patent, manufacturers may hold patents related to novel or improved synthesis processes, purification methods, or specific polymorphic forms of the API. These process patents, if commercially viable and enforced, could offer a competitive advantage to the patent holder but do not prevent others from using the molecule.
• Regulatory Exclusivity: Regulatory data exclusivity periods, tied to the approval of specific new drug applications (NDAs) or the development of new formulations, can influence market dynamics but do not impact the availability of the API for generic use.

The patent landscape for dichlorphenamide API is characterized by the absence of composition-of-matter patents, facilitating generic manufacturing. Sourcing decisions are therefore driven more by manufacturing capability, quality, regulatory compliance, and supply chain reliability than by intellectual property restrictions on the molecule itself.

What are the key market trends and future outlook for dichlorphenamide API?

The market for dichlorphenamide API is characterized by stability, driven by its established therapeutic use and limited growth in indications.

Market Trends:

• Stable Demand: The primary indications for dichlorphenamide (periodic paralysis) are rare diseases, leading to a relatively stable, albeit low, global demand.
• Genericization: The market is largely served by generic API manufacturers.
• Quality as a Differentiator: While price is a factor, stringent regulatory requirements and the critical nature of the API mean that quality, reliability, and GMP compliance are paramount for FDF manufacturers.
• Consolidation Potential: While not currently a major trend, economic pressures or supply chain vulnerabilities could eventually lead to consolidation among API manufacturers.
• Emerging Market Penetration: As healthcare infrastructure develops in emerging markets, the demand for established generic APIs like dichlorphenamide may see incremental increases.

Future Outlook:

The future outlook for dichlorphenamide API is one of continued stability. No significant new therapeutic applications are widely anticipated, nor are there disruptive technological shifts expected in its synthesis or delivery that would drastically alter market dynamics.

• Supply Chain Resilience: Increased emphasis will likely be placed on ensuring supply chain robustness, potentially leading to some diversification of manufacturing locations over the long term, though cost pressures may limit this.
• Regulatory Scrutiny: Ongoing and potentially increasing regulatory scrutiny on API quality and manufacturing processes will remain a constant.
• Price Sensitivity: The market will remain price-sensitive, with FDF manufacturers seeking cost-effective sourcing without compromising on quality.

Overall, the dichlorphenamide API market is mature and predictable, with sourcing decisions hinging on established criteria of quality, regulatory adherence, and reliable supply.

Key Takeaways

• Dichlorphenamide API production is concentrated among a few manufacturers, primarily in India and Europe.
• Regulatory oversight by bodies such as the FDA and EMA is stringent, requiring adherence to GMP standards.
• The API's synthesis involves multiple steps, contributing to its cost, with purification being a critical factor.
• Geopolitical concentration and logistical challenges pose the main supply chain risks.
• Expired composition-of-matter patents allow for generic API production, emphasizing process innovation and supply chain reliability over IP barriers.
• The market is expected to remain stable, with demand driven by rare disease indications and supply decisions based on quality and reliability.

Frequently Asked Questions

1. Are there any novel synthesis routes for dichlorphenamide API currently under development? While incremental process improvements are always sought by manufacturers to enhance yield and reduce costs, there are no widely reported novel synthesis routes for dichlorphenamide API that are on the cusp of commercialization or expected to significantly disrupt the current manufacturing landscape.

2. What is the typical lead time for ordering dichlorphenamide API from manufacturers? Typical lead times can range from 8 to 16 weeks, depending on the manufacturer's production schedule, current inventory levels, and the specific order volume. Rush orders may incur additional costs and are subject to manufacturer availability.

3. How can FDF manufacturers verify the GMP compliance of a new dichlorphenamide API supplier? Verification typically involves reviewing the manufacturer's GMP certification (e.g., FDA Establishment Inspection Report, EMA GMP Certificate), inspecting the manufacturing site, and reviewing batch records and quality control data. Requiring a Drug Master File (DMF) submission also aids in this verification process.

4. Are there any significant environmental concerns associated with dichlorphenamide API manufacturing that could impact supply? The synthesis of halogenated organic compounds can involve the use of hazardous reagents and generate waste streams that require careful management. Manufacturers must comply with local and international environmental regulations regarding waste disposal and emissions. Significant breaches of these regulations could lead to production halts or penalties, impacting supply.

5. What is the typical price range for dichlorphenamide API on the global market? The price of dichlorphenamide API can fluctuate based on volume, manufacturer, quality certifications, and market demand. However, as a generic API, prices are competitive. Wholesale prices for pharmaceutical-grade dichlorphenamide API can range from approximately $200 to $500 USD per kilogram, though this is a general estimate and subject to change based on specific contractual agreements and market conditions.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Placeholder for actual DMF guidance page]

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA Website - Placeholder for actual GMP guidance page]

[3] Central Drugs Standard Control Organization. (n.d.). About CDSCO. Retrieved from [CDSCO Website - Placeholder for actual CDSCO information page]

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website - Placeholder for actual CEP information page]